• We have previously reported DAPK

  2021-07-12

  

  We have previously reported DAPK inhibitors discovered through our structure-based virtual screening (SBVS) research program. In this paper, we describe the general protocol of our in silico approach, and the strategy used to develop hit compounds. In addition, the studies conducted on the structure

• In addition we investigated if the previously reported

  2021-07-12

  

  In addition, we investigated if the previously reported papain inhibitor can inhibit rhodesain, and found that it was not active at inhibiting rhodesain. The vinyl sulfone analogue of () was then synthesized and tested, and it was also inactive towards rhodesain. We then determined the time dependen

• It is now widely known

  2021-07-12

  

  It is now widely known that blockade of CysLT1 receptors strongly inhibits antigen-induced bronchial contractions in specimens isolated from non-asthma subjects. However, this blockade is not complete as shown in the present study and in other literature.4, 15, 16 The results of the current study su

• To the best of our knowledge this study

  2021-07-12

  

  To the best of our knowledge, this study was the first to demonstrate in vitro and in vivo that the lipolytic effect of kinsenoside results from coordination between PKA and AMPK pathways. We validated the lipolytic effect of kinsenoside in vivo and the effect of PKA activation on the modulating AMP

• CPG a metalloenzyme derived from

  2021-07-12

  

  CPG2, a metalloenzyme derived from sp., was the elected enzyme for the first pilot-scale clinical trial of ADEPT. This enzyme has no mammalian homologue and activates glutamic FK 866 hydrochloride sale prodrug derivatives of several nitrogen mustards alkylating agents., , , , , A bond cleavable by C

• In the context of our

  2021-07-12

  

  In the context of our ongoing studies to define the phytochemical and biological properties of oxyprenylated secondary metabolites of plant and fungal origin, we wish to report herein the investigation on the interaction of some natural and semisynthetic O-alkylcoumarins with promising ChE inhibitor

• br EphB as a therapeutic target in

  2021-07-12

  

  EphB4 as a therapeutic target in cancer Eph receptors and ephrins are promising new therapeutic targets in cancer. Various strategies have been employed to evaluate the interference of tumor-promoting effects or the enhancement of tumor suppressive effects. The inhibition of the Eph-ephrin system

• After activation AKT phosphorylates target proteins

  2021-07-12

  

  After activation, AKT phosphorylates target proteins involved in cell growth, metabolism and survival (Manning and Cantley, 2007). For example, AKT phosphorylates the pro-apoptotic protein BAD, preventing it from binding to and inactivating Bcl-xL in mitochondria (Datta et al., 1997). In turn, Bcl-x

• The modification of proteins with the small amino acid prote

  2021-07-03

  

  The modification of proteins with the small 76-amino ak7 receptor protein ubiquitin (Ub) plays a central role in many key cellular processes. Ubiquitylation of a target protein requires the concerted action of a cascade of three enzymes (Figure 1). The ubiquitin-activating enzyme (E1) catalyzes the

• CIC mediated chemoresistance is driven by several factors

  2021-07-02

  

  CIC-mediated chemoresistance is driven by several factors. In our quest to learn about these, we examined the crucial mediators identified earlier in the regulation of CSC survival and chemoresistance, such as BCL2, cleaved Caspase-3, COX-2, and macrophages. Interestingly, we observed a significantl

• L-Carnitine inner salt Various domains of DDR have been show

  2021-07-02

  

  Various domains of DDR1 have been shown to be important for receptor clustering and its oligomeric status. It is now understood that (i) dimerization [7] and higher-order oligomerization [12], [18] of the DDR1 extracellular domain (ECD) enhance its binding to collagen; (ii) DDR1 exists as non-covale

• Overexpression of EP and DDR has been sporadically

  2021-07-02

  

  Overexpression of EP300 and DDR1 has been sporadically reported in the pathogenesis of pulmonary fibrosis and other fibrotic diseases. Zeng et al. reported that EP300 was increased in TGF-β1 treated lung fibroblasts and mediated decreases of SIRT1 expression. Bhattacharyya et al. found that both EP3

• RSL3 Instead of receptor interaction or

  2021-07-02

  

  Instead of receptor interaction or GT activity, we focused on the CPD and autoprocessing. The CPDs from the 2 toxins are highly homologous: each cysteine protease targets an intramolecular substrate and mediates InsP6-induced autoprocessing to release the GTD into host cytosol.40, 41 However, TcdB i

• Henderson et al reported that allergen induced

  2021-07-02

  

  Henderson et al. [20] reported that allergen-induced airway remodeling was blocked by the CysLT1 receptor antagonist montelukast. The development of epithelial thickening and mucus accumulation at relatively small bronchi was also suppressed by montelukast. The CysLT2 receptor antagonist BayCysLT2RA

• The cyclin dependent kinase deactivation is carried out

  2021-07-02

  

  The cyclin-dependent kinase deactivation is carried out by a particular group of proteins cyclin-dependent kinase inhibitors (CDKIs). These group of proteins blocks kinase activity by interfering with the interaction of cyclin-CDK complex [43]. The inhibition of CDK naturally occurs during a G1 phas

15700 records 600/1047 page Previous Next First page 上5页 596597598599600 下5页 Last page